Advertisement

Innovation

Haystack Oncology, a digital oncology and cancer detection company, has raised $56 million in series A financing.

Data from basic blood work and other vitals can accurately project a COVID-19 patient's outcomes, according to a nearly three-year-long study led by Northwell Health's research arm, Feinstein Institutes for Medical Research. 

Advertisement
Advertisement